MediWound (NASDAQ:MDWD) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen cut shares of MediWound (NASDAQ:MDWD) from a sell rating to a strong sell rating in a research note released on Saturday.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price target (down from $32.00) on shares of MediWound in a report on Friday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $33.00.

MediWound Trading Up 0.2%

Shares of MediWound stock opened at $13.56 on Friday. MediWound has a 12-month low of $13.40 and a 12-month high of $20.30. The company has a market cap of $174.27 million, a price-to-earnings ratio of -7.53 and a beta of 0.15. The company’s 50-day moving average price is $14.35 and its 200-day moving average price is $15.97.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative return on equity of 44.77% and a negative net margin of 170.10%.The firm had revenue of $3.09 million during the quarter, compared to analysts’ expectations of $2.59 million. On average, sell-side analysts predict that MediWound will post -2.31 earnings per share for the current year.

Insider Buying and Selling

In other news, Director David Morton Fox purchased 3,537 shares of the stock in a transaction on Monday, June 1st. The shares were acquired at an average price of $14.11 per share, for a total transaction of $49,907.07. Following the completion of the transaction, the director directly owned 22,283 shares of the company’s stock, valued at approximately $314,413.13. This trade represents a 18.87% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 9.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Kotler Kevin purchased a new stake in shares of MediWound in the 4th quarter valued at $6,225,000. Millennium Management LLC lifted its stake in MediWound by 355.6% in the third quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock worth $3,160,000 after purchasing an additional 136,884 shares during the last quarter. UBS Group AG lifted its stake in MediWound by 90.1% in the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock worth $2,678,000 after purchasing an additional 68,756 shares during the last quarter. Sphera Funds Management LTD. boosted its position in MediWound by 24.3% during the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after buying an additional 45,077 shares during the period. Finally, Summit Financial LLC boosted its position in MediWound by 200.1% during the fourth quarter. Summit Financial LLC now owns 47,998 shares of the biopharmaceutical company’s stock valued at $886,000 after buying an additional 32,006 shares during the period. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.